Journal Article

Comparison of ezetimibe and atorvastatin versus atorvastatin alone on short-term major adverse cardiac events after percutaneous coronary intervention, a double-blind placebo-controlled randomized clinical trial

Sobhani, Seyed Alireza, Farshidi, Hossein, Bijani, Badri, Dastsouz, Farideh, Abbaszadeh, Shahin

2025

Overview

Background Major cardiovascular events (MACE) after percutaneous coronary intervention (PCI) are among the most common causes of death in patients. Lipid-lowering strategies seem to affect these events. Reaching the best regimen for controlling lipid abnormalities is important. This study aimed to compare the effect of ezetimibe and atorvastatin versus atorvastatin alone in short-term major cardiovascular events in patients after PCI in Bandar Abbas in 2018. Methods This double-blinded randomized controlled trial was done in Bandar Abbas in 2018 on 224 patients. Patients were randomly divided into two groups either to receive ezetimibe and atorvastatin (group A) or atorvastatin alone (group B). Patients were followed for 1 month for major cardiovascular events and drug side effects. Data was analyzed using SPSS software. Results Patients in the two groups had similar baseline characteristics. The mean low-density lipoproteins (LDL) level was 69.83 ± 28.8 in group A and 82.45 ± 29.9 in group B ( P  = 0.014). At the end of the study, high-sensitivity C-reactive protein (hs-CRP) values were notably lower in group A ( P value = 0.005). Three (2.7%) patients in group A and 1 patient (0.9%) in group B had a myocardial infarction ( P value = 0.313). Also, 11 patients (9.8%) in group A and 13 patients (11.6%) in group B had unstable angina ( P value = 0.666). No patients had death, cerebrovascular event, or stent thrombosis in the two groups. Conclusion Although adding ezetimibe to atorvastatin can decrease LDL and hs-CRP levels in short-term follow-up; it is not effective in lowering short-term major cardiovascular events in patients after PCI. Studies with longer-term follow-up are recommended. Trial registration IRCT, IRCT20171028037047N1. Registered on 22 June 2018, https://irct.behdasht.gov.ir/trial/28808 .

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Aged / Angina pectoris / Angioplasty / Anticholesteremic Agents - administration & dosage / Anticholesteremic Agents - adverse effects / Anticholesteremic Agents - therapeutic use / Atherosclerosis / Atorvastatin / Atorvastatin - administration & dosage / Atorvastatin - adverse effects / Atorvastatin - therapeutic use / Biomedicine / Blood lipids / Blood pressure / Body mass index / C-reactive protein / C-Reactive Protein - metabolism / Cardiac patients / Cardiovascular disease / Chi-square test / Clinical outcomes / Clinical trials / Coronary intervention / Coronary vessels / Creatinine / Double-Blind Method / Drug Therapy, Combination / Enzymes / Eptifibatide / Ezetimibe / Ezetimibe - administration & dosage / Ezetimibe - adverse effects / Ezetimibe - therapeutic use / Female / Health Sciences / Heart attacks / Humans / Independent sample / Inflammation / Intervention / Lipids / Low density lipoproteins / Major adverse cardiovascular events / Male / Medical imaging / Medical research / Medicine / Medicine & Public Health / Medicine, Experimental / Middle Aged / Mortality / Nonsteroidal anti-inflammatory drugs / Patients / Percutaneous Coronary Intervention - adverse effects / Placebo effect / Statins / Statistics for Life Sciences / Thrombosis / Time Factors / Transluminal angioplasty / Treatment Outcome / Vein & artery diseases